Hans‐Peter Gerber

27.8k total citations · 9 hit papers
91 papers, 21.1k citations indexed

About

Hans‐Peter Gerber is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hans‐Peter Gerber has authored 91 papers receiving a total of 21.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 45 papers in Molecular Biology and 33 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hans‐Peter Gerber's work include Angiogenesis and VEGF in Cancer (31 papers), Monoclonal and Polyclonal Antibodies Research (31 papers) and HER2/EGFR in Cancer Research (23 papers). Hans‐Peter Gerber is often cited by papers focused on Angiogenesis and VEGF in Cancer (31 papers), Monoclonal and Polyclonal Antibodies Research (31 papers) and HER2/EGFR in Cancer Research (23 papers). Hans‐Peter Gerber collaborates with scholars based in United States, Switzerland and France. Hans‐Peter Gerber's co-authors include Napoleone Ferrara, Jennifer LeCouter, Kenneth J. Hillan, William Novotny, Vishva M. Dixit, Ajay K. Malik, Xiao Liang, Jeanie Park, Fabrizio Condorelli and Joe Kowalski and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Hans‐Peter Gerber

89 papers receiving 20.5k citations

Hit Papers

The biology of VEGF and i... 1994 2026 2004 2015 2003 2004 1998 1999 2007 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The biology of VEGF and its receptors
    2003 7.6k citations Napoleone Ferrara, Hans‐Peter Gerber et al. profile →
  2. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    2004 2.0k citations Napoleone Ferrara, Kenneth J. Hillan et al. profile →
  3. Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells
    1998 782 citations Hans‐Peter Gerber, Napoleone Ferrara et al. profile →
  4. VEGF is required for growth and survival in neonatal mice
    1999 727 citations Hans‐Peter Gerber, Kenneth J. Hillan et al. profile →
  5. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
    2007 673 citations Farbod Shojaei, Ajay K. Malik et al. profile →
  6. Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes
    1997 642 citations Hans‐Peter Gerber, Napoleone Ferrara et al. profile →
  7. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
    2002 567 citations Hans‐Peter Gerber, Ajay K. Malik et al. profile →
  8. Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1
    2003 513 citations Jennifer LeCouter, Dirk Moritz et al. Science profile →
  9. Transcriptional Activation Modulated by Homopolymeric Glutamine and Proline Stretches
    1994 510 citations Hans‐Peter Gerber et al. Science profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Hans‐Peter Gerber 12.1k 5.7k 4.6k 2.5k 2.3k 91 21.1k
Gavin Thurston 13.8k 1.1× 5.5k 1.0× 4.1k 0.9× 2.3k 0.9× 1.4k 0.6× 168 22.1k
Lawrence F. Brown 13.7k 1.1× 6.1k 1.1× 5.2k 1.1× 2.4k 1.0× 1.4k 0.6× 111 23.2k
Eli Keshet 13.3k 1.1× 2.9k 0.5× 6.5k 1.4× 2.5k 1.0× 2.4k 1.0× 117 23.4k
Masabumi Shibuya 12.6k 1.0× 4.8k 0.8× 3.8k 0.8× 1.6k 0.6× 993 0.4× 215 20.7k
Donald R. Senger 11.3k 0.9× 3.3k 0.6× 4.4k 0.9× 2.2k 0.9× 1.5k 0.7× 89 18.7k
Patrìcia A. D'Amore 17.0k 1.4× 3.6k 0.6× 3.9k 0.8× 2.2k 0.9× 4.5k 2.0× 233 30.0k
Lena Claesson‐Welsh 22.2k 1.8× 6.9k 1.2× 5.8k 1.2× 2.2k 0.9× 1.6k 0.7× 256 32.3k
Shoukat Dedhar 15.8k 1.3× 5.1k 0.9× 4.1k 0.9× 1.6k 0.6× 965 0.4× 260 26.4k
Rolf A. Brekken 9.3k 0.8× 6.4k 1.1× 4.4k 1.0× 1.7k 0.7× 950 0.4× 271 19.5k
Kevin C. Gatter 12.7k 1.0× 8.2k 1.4× 8.4k 1.8× 3.5k 1.4× 1.5k 0.7× 311 26.8k

Countries citing papers authored by Hans‐Peter Gerber

Since Specialization
Citations

This map shows the geographic impact of Hans‐Peter Gerber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Peter Gerber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Peter Gerber more than expected).

Fields of papers citing papers by Hans‐Peter Gerber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Peter Gerber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Peter Gerber. The network helps show where Hans‐Peter Gerber may publish in the future.

Co-authorship network of co-authors of Hans‐Peter Gerber

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Peter Gerber. A scholar is included among the top collaborators of Hans‐Peter Gerber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Peter Gerber. Hans‐Peter Gerber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yuan, Robert, Andrew McGeehan, Sihong Zhou, et al.. (2025). The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death. Molecular Cancer Therapeutics. 24(9). 1428–1441. 1 indexed citations
2.
Sung, Matthew, Xingzhi Tan, Bingwen Lu, et al.. (2017). Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1). Molecular Cancer Therapeutics. 17(1). 243–253. 155 indexed citations
3.
Pirie‐Shepherd, Steven, Cory L. Painter, Pamela Whalen, et al.. (2017). Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients. PLoS ONE. 12(7). e0179561–e0179561. 7 indexed citations
4.
Guffroy, Magali, Hadi Falahatpisheh, John M. Kreeger, et al.. (2016). Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring. Clinical Cancer Research. 23(7). 1760–1770. 47 indexed citations
5.
Sapra, Puja, Marc Damelin, John F. DiJoseph, et al.. (2012). Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells. Molecular Cancer Therapeutics. 12(1). 38–47. 51 indexed citations
6.
Oflazoglu, Ezogelin, Tamar E. Boursalian, Weiping Zeng, et al.. (2009). Blocking of CD27-CD70 Pathway by Anti-CD70 Antibody Ameliorates Joint Disease in Murine Collagen-Induced Arthritis. The Journal of Immunology. 183(6). 3770–3777. 47 indexed citations
7.
Gerber, Hans‐Peter, Peter D. Senter, & Iqbal S. Grewal. (2009). Antibody drug-conjugates targeting the tumor vasculature. mAbs. 1(3). 247–253. 58 indexed citations
8.
Kim, Kristine M., Charlotte F. McDonagh, Lori Westendorf, et al.. (2008). Anti-CD30 diabody-drug conjugates with potent antitumor activity. Molecular Cancer Therapeutics. 7(8). 2486–2497. 73 indexed citations
9.
McDonagh, Charlotte F., Kristine M. Kim, Eileen Turcott, et al.. (2008). Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Molecular Cancer Therapeutics. 7(9). 2913–2923. 60 indexed citations
10.
Oflazoglu, Ezogelin, Kim M. Kissler, Eric L. Sievers, Iqbal S. Grewal, & Hans‐Peter Gerber. (2008). Combination of the anti‐CD30‐auristatin‐E antibody‐drug conjugate (SGN‐35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. British Journal of Haematology. 142(1). 69–73. 85 indexed citations
11.
Garcia, Claudia M., Ying‐Bo Shui, Randall S. Johnson, et al.. (2008). The function of VEGF-A in lens development: Formation of the hyaloid capillary network and protection against transient nuclear cataracts. Experimental Eye Research. 88(2). 270–276. 23 indexed citations
12.
Gerber, Hans‐Peter, Ivan J. Stone, Mechthild Jonas, et al.. (2007). Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies. Molecular Cancer Therapeutics. 6. 2 indexed citations
13.
Shojaei, Farbod, Xiumin Wu, Ajay K. Malik, et al.. (2007). Tumor refractoriness to anti-VEGF treatment mediated by CD11b+Gr1+ myeloid cells. Molecular Cancer Therapeutics. 6. 1 indexed citations
14.
Yamamoto, Hiroaki, et al.. (2007). Epithelial–vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. Developmental Biology. 308(1). 44–53. 116 indexed citations
15.
Tejada, Max L., Lanlan Yu, Jianying Dong, et al.. (2006). Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma. Clinical Cancer Research. 12(9). 2676–2688. 94 indexed citations
16.
Baldwin, Megan E., Xiao Huan Liang, Johanna Busch, et al.. (2004). Generation of mice carrying floxed VEGFR-1 and VEGFR-2 alleles to study the effects of postnatal gene ablation on angiogenesis and hematopoiesis. Cancer Research. 64. 596–596. 1 indexed citations
17.
Tang, Nan, Lianchun Wang, Jeffrey D. Esko, et al.. (2004). Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell. 6(5). 485–495. 446 indexed citations
18.
LeCouter, Jennifer, Dirk Moritz, Bing Li, et al.. (2003). Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1. Science. 299(5608). 890–893. 513 indexed citations breakdown →
19.
Inoue, Masahiro, Jeffrey H. Hager, Napoleone Ferrara, Hans‐Peter Gerber, & Douglas Hanahan. (2002). VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell. 1(2). 193–202. 306 indexed citations
20.
Gerber, Hans‐Peter, et al.. (1982). [Prevention of dextran-induced anaphylactoid reactions by preinjection of 20 ml hapten in 12 000 patients in Switzerland].. PubMed. 71(26). 1092–100. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gavin Thurston Breakdown of academic impact, for papers by Lawrence F. Brown Breakdown of academic impact, for papers by Eli Keshet Breakdown of academic impact, for papers by Masabumi Shibuya Breakdown of academic impact, for papers by Donald R. Senger Breakdown of academic impact, for papers by Patrìcia A. D'Amore Breakdown of academic impact, for papers by Lena Claesson‐Welsh Breakdown of academic impact, for papers by Shoukat Dedhar Breakdown of academic impact, for papers by Rolf A. Brekken Breakdown of academic impact, for papers by Kevin C. Gatter
Rankless by CCL
2026